Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (No 2)

Link copied
Case Copied 20 min read

FEDERAL COURT OF AUSTRALIA

Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (No 2) [2022] FCA 369  

File number: NSD 1370 of 2019
Judgment of: BURLEY J
Date of judgment: 11 April 2022
Catchwords:

PATENTS – form of orders to give effect to the Court’s reasons – where infringement case was conducted on the basis of batch records supplied by respondents – where respondents admitted that batch records provided were representative of batches sold by respondents in Australia – where applicants successful in establishing that certain batches fell within scope of relevant claims – whether declarations appropriate – where patent has now expired – whether injunctions appropriate

COSTS – where respondents contend that no batches sold in Australia infringed – determination of costs of infringement claim deferred until after hearing on quantum – where respondents failed in defensive cross-claim – respondents to pay costs of cross-claim – question of costs of infringement claim deferred

Legislation: Patents Act 1990 (Cth) s 19
Cases cited:

Idenix Pharmaceuticals LLC v Gilead Sciences Pty Ltd (No 2) [2018] FCAFC 7

Juno Pharmaceuticals Pty Ltd v Millennium Pharmaceuticals, Inc [2019] FCA 526

Park v Brothers [2005] HCA 73; 222 ALR 421

Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92

Selvaratnam v St George - A Division of Westpac Banking Corporation (No 2) [2021] FCA 486

Smith v New South Wales Bar Association [1992] HCA 36; 176 CLR 256

Truth About Motorways Pty Ltd v Macquarie Infrastructure Management Ltd [2000] HCA 11; 200 CLR 591

Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 37
Date of hearing: 17 March 2022
Counsel for the Applicants: Mr C Dimitriadis SC with Ms L Thomas
Solicitor for the Applicants: DLA Piper Australia
Counsel for the Respondents: Mr A Ryan SC with Mr J Elks
Solicitor for the Respondents: Biopharmalex

ORDERS

NSD 1370 of 2019
BETWEEN:

PHARMACIA LLC

First Applicant

PFIZER AUSTRALIA PTY LTD ACN 008 422 348

Second Applicant

AND:

JUNO PHARMACEUTICALS PTY LTD ACN 156 303 650

First Respondent

NEO HEALTH (AUSTRALIA) PTY LTD ACN 605 322 763

Second Respondent

AND BETWEEN:

JUNO PHARMACEUTICALS PTY LTD ACN 156 303 650 (and another named in the Schedule)

First Cross-Claimant

AND:

PHARMACIA LLC (and another named in the Schedule)

First Cross-Respondent

ORDER MADE BY:

BURLEY J

DATE OF ORDER:

11 APRIL 2022

THE COURT DECLARES THAT:

1.Exemplar batches 31604, 31605 and 31606 of the Respondents’ parecoxib products (the Infringing Exemplar Batches) contain a composition as referred to in claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and 41 of Australian Patent No. 2002256031 (the Patent).

2.Exemplar batches 31601, 31602 and 31603 of the Respondents’ parecoxib products (the Non-Infringing Exemplar Batches) do not contain a composition as referred to in claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2022] FCA 369
Decision Date

CaseChat Overview and Summary

The case Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (No 2) concerns a dispute between Pharmacia LLC, the patent holder, and Juno Pharmaceuticals Pty Ltd and Neo Pharmaceuticals Pty Ltd, the respondents, regarding the infringement of a pharmaceutical patent. The Federal Court of Australia was tasked with deciding on the form of orders to give effect to the Court's reasons in the infringement case, the appropriateness of declarations and injunctions, and the costs associated with the proceedings.

The legal issues that the court needed to decide included whether declarations of infringement should be made, whether injunctions should be granted, and who should pay the costs of the proceedings. The applicants argued that the respondents had admitted the batch records provided were representative of the batches sold in Australia, and that certain batches fell within the scope of the relevant claims. The respondents, on the other hand, contended that no batches sold in Australia infringed the patent, and therefore, declaratory and injunctive relief was not appropriate.

The court reasoned that while declarations regarding the composition of the exemplar batches and their infringement status should be made, injunctions should not be granted as the patent had expired. The court also held that the respondents should pay the costs of the cross-claim, but deferred making orders on the question of costs on the infringement claim pending the assessment of the respondents' liability for pecuniary relief.

The final orders made by the court were that declarations should be made regarding the composition of the exemplar batches and their infringement status, but injunctions should not be granted. The respondents were to pay the costs of the cross-claim, and the question of costs on the infringement claim was deferred pending further assessment. The proceeding was listed for case management and further directions on the applicants' claim for pecuniary relief.

Orders

Orders of the court

4. The cross-claim be dismissed.

5. Juno and Neo pay the Applicants’ costs of the cross-claim, such costs to be taxed in the absence of agreement.

6. The proceeding be listed for case management, including further directions on the Applicants’ claim for pecuniary relief, on 16 May 2022.

THE COURT CERTIFIES THAT:

7. For the purposes of section 19 of the Patents Act 1990 (Cth), the validity of each of claims 1 to 5, 7, 11 to 15, 17 to 24, 26 to 28, 34 to 41 and 42 of the Patent was questioned unsuccessfully in this proceeding.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

On 15 February 2022 I delivered reasons addressing the substantive disputes in these proceedings, and made orders that the parties confer and provide draft short minutes of order giving effect to those reasons: Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 (judgment or J). The parties have been unable to agree on three aspects of the orders concerning the infringement case advanced against the respondents, namely: (1) whether declarations of infringement should be made; (2) whether injunctions should be granted; and (3) who should pay the costs of the proceedings. These reasons assume familiarity with the judgment, and adopt the definitions used within it. The applicants contend that the following declaratory and injunctive orders should be made:THE COURT DECLARES THAT:1.Exemplar batches 31604, 31605 and 31606 of the Respondents’ parecoxib products (the Infringing Exemplar Batches) contain a composition as referred to in claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and 41 of Australian Patent No. 2002256031 (the Patent).2.Exemplar batches 31601, 31602 and 31603 of the Respondents’ parecoxib products (the Non-Infringing Exemplar Batches) do not contain a composition as referred to in claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and 41 of the Patent.2A.Exemplar batches 31601, 31602, 31603 31604, 31605 and 31606 of the Respondents’ parecoxib products do not contain a composition as referred to in claims 7, 26, 27, 28, 30 and 42 of the Patent.3.The First Respondent (Juno) has infringed and threatened to infringe each of claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and 41 of the Patent, including by offering for sale, selling and supplying in Australia, without the licence or authority of the Applicants, parecoxib products corresponding to the Infringing Exemplar Batches.4.The Second Respondent (Neo) has infringed and threatened to infringe each of claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and 41 of the Patent, including by supplying in Australia, without the licence or authority of the Applicants, parecoxib products corresponding to the Infringing Exemplar Batches.THE COURT ORDERS THAT:5.Juno (whether by itself, its directors, officers, servants, agents or howsoever otherwise) be restrained, during the term of the Patent, from infringing claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and 41 of the Patent, including without limitation from, without the licence or authority of the Applicants, importing, making, using, offering to sell, supply or otherwise dispose of, selling, supplying or otherwise disposing of, keeping for the purpose of sale, supply or other disposal, or otherwise exploiting, parecoxib products corresponding to the Infringing Exemplar Batches.6.Neo (whether by itself, its directors, officers, servants, agents or howsoever otherwise) be restrained, during the term of the Patent, from infringing claims 1, 4, 5, 11, 14, 15, 17, 18, 19, 20, 21, 24, 34, 35, 36, 37, 38, 39, 40 and 41 of the Patent, including without limitation from, without the licence or authority of the Applicants, importing, making, using, offering to sell, supply or otherwise dispose of, selling, supplying or otherwise disposing of, keeping for the purpose of sale, supply or other disposal, or otherwise exploiting, parecoxib products corresponding to the Infringing Exemplar Batches.

Ratio Decidendi

Legal Principle Established

For the reasons set out below declarations set out in Orders 1, 2 and 2A should be made, but not declarations 3 and 4 or the injunctions in proposed Orders 5 and 6. I consider that the respondents should be required to pay the costs of the cross claim, but will defer making orders on the question of costs on the infringement claim, pending the resolution of the assessment of the respondents’ liability for pecuniary relief. Although a draft order proposes, by consent, that I make an order in relation to the time for the parties to seek leave to appeal, I do not propose to do so, as it is a matter for each party to make such an application in accordance with the usual requirements, should they choose to do so. 2. DECLARATIONS AND INJUNCTIONS 2.1 The submissions The applicants submit that the hearing of the infringement aspect of the case was conducted by reference to documents relating to six exemplar batches (batch records) which were produced by the respondents during the course of the preparatory stages of the proceedings. Those documents were exhibited to an affidavit given by Mr Tyacke on 16 October 2020 and, having regard to the correspondence to which that affidavit refers, the applicants contend that the production of the batch records amounted to an admission that they were representative of products that Juno supplies in Australia under ARTG registrations No. 282353 and 282354. The applicants submit that the proceedings and the hearing were conducted on that basis, noting that an attempt by the respondents during the hearing to tender further documents concerning the composition of the Juno products failed. The applicants submit that the Court found, at J[14], that three of the six exemplar batches fell within the scope of certain claims of the patent, and three did not, and concluded that the applicants are entitled to injunctive relief to restrain infringement. They submit that the proposed declarations sought in Orders 1 and 2 (and a later notified Order 2A) reflect the findings made in relation to the batches, and that it is appropriate for the Court to also make the declarations in Orders 3 and 4 having regard to the Court’s findings and the admissions made by the respondents. They submit that the injunctions to restrain infringement in Orders 5 and 6 are warranted but accept that given the then impending expiration of the patent, they would not oppose an order staying those injunctions. The respondents submit that declaratory relief is not appropriate for three reasons. First, because it is beyond the applicants’ pleaded case broadly because none of the exemplar batches were ever imported into Australia under the two ARTG registrations held by Juno. Secondly, because it is inappropriate to make declarations that have no utility which, the respondents contend, would be the case here because none of the exemplar batches were ever imported into Australia and, as such, cannot be considered to be “infringing” under the Patents Act 1990 (Cth). Thirdly, they submit that the patent expires on 2 April 2022 in any event.